Literature DB >> 8406497

Four novel FBN1 mutations: significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome.

H C Dietz1, I McIntosh, L Y Sakai, G M Corson, S C Chalberg, R E Pyeritz, C A Francomano.   

Abstract

Defects of fibrillin (FBN1), a glycoprotein component of the extracellular microfibril, cause Marfan syndrome. This disorder is characterized by marked inter- and intrafamilial variation in phenotypic severity. To understand the molecular basis for this clinical observation, we have screened the fibrillin gene (FBN1) on chromosome 15, including the newly cloned 5' coding sequence, for disease-producing alterations in a panel of patients with a wide range of manifestations and clinical severity. All the missense mutations identified to date, including two novel mutations discussed here, are associated with classic and moderate to severe disease and occur at residues with putative significance for calcium binding to epidermal growth factor (EGF)-like domains. In contrast, two new mutations that create premature signals for termination of translation of mRNA and are associated with reduction in the amount of mutant allele transcript produce a range of phenotypic severity. The patient with the lowest amount of mutant transcript has the mildest disease. These data support a role for altered calcium binding to EGF-like domains in the pathogenesis of Marfan syndrome and suggest a dominant negative mechanism for the pathogenesis of this disorder.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8406497     DOI: 10.1006/geno.1993.1349

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  80 in total

1.  Muscle fibrillin deficiency in Marfan's syndrome myopathy.

Authors:  W M H Behan; C Longman; R K H Petty; P Comeglio; A H Child; M Boxer; P Foskett; D G F Harriman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-05       Impact factor: 10.154

2.  New fibrillin gene mutation - possible cause of ascending aortic dilation in patients with aortic valve disease: Preliminary results.

Authors:  Ján Dudra; Jaroslav Lindner; Ivan Vaněk; Jana Simova; Ivan Mazura; Ivo Miler; Jana Ciháková; Pavel Capek; Josef Belák
Journal:  Int J Angiol       Date:  2009

Review 3.  The molecular genetics of Marfan syndrome and related microfibrillopathies.

Authors:  P N Robinson; M Godfrey
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

Review 4.  Marfan's syndrome.

Authors:  Daniel P Judge; Harry C Dietz
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

5.  Two molecular pathways (NMD and ERAD) contribute to a genetic epilepsy associated with the GABA(A) receptor GABRA1 PTC mutation, 975delC, S326fs328X.

Authors:  Jing-Qiong Kang; Wangzhen Shen; Robert L Macdonald
Journal:  J Neurosci       Date:  2009-03-04       Impact factor: 6.167

6.  Of mice and Marfan: genetic linkage analyses of the fibrillin genes, Fbn1 and Fbn2, in the mouse genome.

Authors:  C Goldstein; P Liaw; S A Jimenez; A M Buchberg; L D Siracusa
Journal:  Mamm Genome       Date:  1994-11       Impact factor: 2.957

7.  Nonsense mutations in hERG cause a decrease in mutant mRNA transcripts by nonsense-mediated mRNA decay in human long-QT syndrome.

Authors:  Qiuming Gong; Li Zhang; G Michael Vincent; Benjamin D Horne; Zhengfeng Zhou
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

8.  Clinical heterogeneity and novel mutations in the glycerol kinase gene in three families with isolated glycerol kinase deficiency.

Authors:  D R Sjarif; R J Sinke; M Duran; F A Beemer; W J Kleijer; J K Ploos van Amstel; B T Poll-The
Journal:  J Med Genet       Date:  1998-08       Impact factor: 6.318

Review 9.  Identification of defects in the fibrillin gene and protein in individuals with the Marfan syndrome and related disorders.

Authors:  D M Milewicz
Journal:  Tex Heart Inst J       Date:  1994

10.  Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome.

Authors:  Daniel P Judge; Nancy J Biery; Douglas R Keene; Jessica Geubtner; Loretha Myers; David L Huso; Lynn Y Sakai; Harry C Dietz
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.